Rigerna is an innovative siRNA biotech committed and dedicated to discovering drugs for diseases with unmet medical needs. Based on proprietary modification platforms, the company has brought the initial pipeline into Phase1 clinical trial, aiming to become first-in-class siRNA drug for IgA nephropathy. In addition, Rigerna has discovered various extra-hepatic siRNA delivery systems, including a novel kidney-targeting approach and achieved Proof-of-Concept in Non-Human Primates recently. Located in Suzhou/Beijing, Rigerna has attracted various experts in oligonucleotide therapies and innovative drug development. We would like to seek diverse collaborations with Pharmaceutical and Biotech companies.